Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States
The Journal of Infectious Diseases · 15.04.2025 · 231 (4) · e743-e753
DOI: 10.1093/infdis/jiaf007 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 08.01.2025. Verfasst von Leora R Feldstein und 28 weiteren Autor:innen. Beteiligte Einrichtung: Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preven…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, SARS-CoV-2, Vaccine Efficacy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Michigan, Kaiser Foundation Hospitals, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Understanding protection against SARS-CoV-2 infection by vaccine and hybrid immunity is important for informing public health strategies as new variants emerge.
Methods
We analyzed data from 3 cohort studies spanning 1 September 2022 to 31 July 2023 to estimate COVID-19 vaccine effectiveness (VE) against SARS-CoV-2 infection and symptomatic COVID-19 among adults with and without prior infection in the United States. Participants collected weekly nasal swabs irrespective of symptoms, participated in annual blood draws, and completed periodic surveys, which included vaccination status and infection history. Swabs were tested molecularly for SARS-CoV-2. VE was estimated by Cox proportional hazards models for the hazard ratios of infections, adjusting for covariates. VE was calculated considering prior infection and recency of vaccination.
Results
Among 3344 adults, the adjusted VE of a bivalent vaccine against infection was 37.2% (95% CI, 12.3%–55.7%) within 7 to 59 days of vaccination and 21.1% (95% CI, −0.5% to 37.1%) within 60 to 179 days of vaccination when compared with participants who were unvaccinated or had received an original monovalent vaccine dose ≥180 days prior. Overall, the adjusted VE of a bivalent vaccine against infection, in conjunction with prior infection, was 62.2% (95% CI, 46.0%–74.5%) within 7 to 179 days of vaccination and 39.4% (95% CI, 12.5%–61.6%) at ≥180 days when compared with naive participants who were unvaccinated or had received a monovalent vaccine dose ≥180 days prior.
Conclusions
Adults with prior infection and recent vaccination had high protection against infection and symptomatic illness. Recent vaccination alone provided moderate protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington.
- Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of Pediatrics, University of Washington, Seattle Children's Research Institute, Seattle, Washington.
- Kaiser Permanente Center for Health Research, Portland, Oregon.
- Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
ORCID-Profile: Leora R Feldstein, Jasmine Ruffin, Ryan E Wiegand, Melissa Briggs-Hagen, Helen Y Chu, Janet A Englund, Jennifer L Kuntz, Adam S Lauring, Claire M Midgley, Sharon Saydah, Ine Sohn, H Keipp Talbot, Ana A Weil, Carlos G Grijalva
Förderung
- University of Michigan
- Kaiser Foundation Hospitals
- National Institute of Allergy and Infectious Diseases
- Vanderbilt University
- Clinical Translational Science Award Program
- NCIRD CDC HHS
- NIH HHS
- NIAID NIH HHS
Zitieren
APA
Feldstein, L. R., Ruffin, J., Wiegand, R. E., Borkowf, C. B., James-Gist, J., Babu, T. M., Briggs-Hagen, M., Chappell, J., Chu, H. Y., Englund, J. A., Kuntz, J. L., Lauring, A. S., Lo, N., Carone, M., Lockwood, C., Martin, E. T., Midgley, C. M., Monto, A. S., Naleway, A. L., …, & Grijalva, C. G. (2025). Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States. The Journal of Infectious Diseases, 231(4), e743-e753. https://doi.org/10.1093/infdis/jiaf007
Vancouver
Feldstein LR, Ruffin J, Wiegand RE, Borkowf CB, James-Gist J, Babu TM, et al. Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States. The Journal of Infectious Diseases. 2025;231(4):e743-e753. doi:10.1093/infdis/jiaf007
BibTeX
@article{Feldstein2025,
author = {Feldstein, Leora R and Ruffin, Jasmine and Wiegand, Ryan E and Borkowf, Craig B and James-Gist, Jade and Babu, Tara M and Briggs-Hagen, Melissa and Chappell, James and Chu, Helen Y and Englund, Janet A and Kuntz, Jennifer L and Lauring, Adam S and Lo, Natalie and Carone, Marco and Lockwood, Christina and Martin, Emily T and Midgley, Claire M and Monto, Arnold S and Naleway, Allison L and Ogilvie, Tara and Saydah, Sharon and Schmidt, Mark A and Schmitz, Jonathan E and Smith, Ning and Sohn, Ine and Starita, Lea and Talbot, H Keipp and Weil, Ana A and Grijalva, Carlos G},
title = {Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {231},
number = {4},
pages = {e743--e753},
doi = {10.1093/infdis/jiaf007}
}
EUVIMED